TABLE 2.
Functional properties of taro.
| Name | Study | Effect | Results | Reference |
|---|---|---|---|---|
| 2% (w/v) Taro | Growth and adherence of Lactobacillus species (in vitro) | Improvement of human gut microbiota through prebiotic potential of taro | ↑ growth of L. acidophilus, L. paracasei, and L. plantarum ↑ self‐agglutination of L. paracasei | Saxby et al. (2019) |
| Aqueous extract of taro | Streptococcus mutans | Antimicrobial activity | ↓ growth | Singh et al., (2012) |
| Ethanolic extract of taro | Alloxan‐induced diabetic mice | Antihyperglycemic effect | Reduced glycemic activity | Singh et al.(2012) |
| Extract of taro 400 mg/kg bw | Male Sprague Dawley rats | Antidiabetic and antianemic effect | Inhibited aldose reductase enzyme activity, increased production of hemoglobin | Sulistiani et al. (2020) |
| Ethanolic leaves concentrate | Wister rats, granuloma model | Anti‐inflammatory activity | Calmed the inflammation | Keerthy and Joshi (2019) |
| Ethanolic and aqueous extract produced five digalactosyl‐diacylglycerols (DGDG) and three monogalactosyl‐diacylglycerols (MGDG) | Human Caco cell lines | Anticholesterol synthesis, declined cholesterol‐induced colorectal cancer (CRC) | Inhibition of human lanosterol synthase (hOSC), declining risk of CRC | |
| Ethanolic taro leaf extracts 10–50 mg/mL | Earth worms | In vitro anthelmintic activity | Potent paralysis and death time | Kubde et al. (2010) |
| 25% Alcoholic concentration of taro leaf extract | Alternaria ricini and Alternaria solani | In vitro antifungal activity | Inhibition of pathogenic growth | Mengane (2015) |
| Taro leaf juice | In vitro rat liver slice model | Hepatotoxins (CCl4 and acetaminophen) induced lipid peroxidative reactions | Prevented the elicit of these reactions and protected liver | Patil and Ageely (2011) |